| Risk of progression and survival in multiple myeloma relapsing after therapy with IMiDs and bortezomib: a multicenter international myeloma working group study SK Kumar, JH Lee, JJ Lahuerta, G Morgan, PG Richardson, J Crowley, ... Leukemia 26 (1), 149-157, 2012 | 1006 | 2012 |
| Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma PI Croucher, CM Shipman, J Lippitt, M Perry, K Asosingh, A Hijzen, ... Blood, The Journal of the American Society of Hematology 98 (13), 3534-3540, 2001 | 456 | 2001 |
| Bone marrow stromal cell–derived exosomes as communicators in drug resistance in multiple myeloma cells J Wang, A Hendrix, S Hernot, M Lemaire, E De Bruyne, ... Blood, The Journal of the American Society of Hematology 124 (4), 555-566, 2014 | 441 | 2014 |
| International Myeloma Working Group recommendations for the diagnosis and management of myeloma-related renal impairment MA Dimopoulos, P Sonneveld, N Leung, G Merlini, H Ludwig, E Kastritis, ... Journal of Clinical Oncology 34 (13), 1544-1557, 2016 | 435 | 2016 |
| Hypoxia promotes dissemination of multiple myeloma through acquisition of epithelial to mesenchymal transition-like features AK Azab, J Hu, P Quang, F Azab, C Pitsillides, R Awwad, B Thompson, ... Blood, The Journal of the American Society of Hematology 119 (24), 5782-5794, 2012 | 349 | 2012 |
| Osteoclasts control reactivation of dormant myeloma cells by remodelling the endosteal niche MA Lawson, MM McDonald, N Kovacic, W Hua Khoo, RL Terry, J Down, ... Nature communications 6 (1), 8983, 2015 | 345 | 2015 |
| Zoledronic acid treatment of 5T2MM‐bearing mice inhibits the development of myeloma bone disease: evidence for decreased osteolysis, tumor burden and angiogenesis, and … PI Croucher, H De Raeve, MJ Perry, A Hijzen, CM Shipman, J Lippitt, ... Journal of Bone and Mineral Research 18 (3), 482-492, 2003 | 335 | 2003 |
| Cell biology of liver endothelial and Kupffer cells. B Smedsrød, PJ De Bleser, F Braet, P Lovisetti, K Vanderkerken, E Wisse, ... Gut 35 (11), 1509, 1994 | 311 | 1994 |
| Inhibiting Dickkopf‐1 (Dkk1) removes suppression of bone formation and prevents the development of osteolytic bone disease in multiple myeloma DJ Heath, AD Chantry, CH Buckle, L Coulton, JD Shaughnessy Jr, ... Journal of Bone and Mineral Research 24 (3), 425-436, 2009 | 302 | 2009 |
| Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma K Vanderkerken, E De Leenheer, C Shipman, K Asosingh, A Willems, ... Cancer Research 63 (2), 287-289, 2003 | 231 | 2003 |
| IGF-1 receptor tyrosine kinase inhibition by the cyclolignan PPP induces G2/M-phase accumulation and apoptosis in multiple myeloma cells T Strömberg, S Ekman, L Girnita, LY Dimberg, O Larsson, M Axelson, ... Blood 107 (2), 669-678, 2006 | 198 | 2006 |
| Liver cell heterogeneity: functions of non-parenchymal cells L Bouwens, P De Bleser, K Vanderkerken, B Geerts, E Wisse Enzyme 46 (1-3), 155-168, 1992 | 197 | 1992 |
| In anemia of multiple myeloma, hepcidin is induced by increased bone morphogenetic protein 2 K Maes, E Nemeth, GD Roodman, A Huston, F Esteve, C Freytes, ... Blood, The Journal of the American Society of Hematology 116 (18), 3635-3644, 2010 | 175 | 2010 |
| Organ involvement and phenotypic adhesion profile of 5T2 and 5T33 myeloma cells in the C57BL/KaLwRij mouse K Vanderkerken, H De Raeve, E Goes, S Van Meirvenne, J Radl, ... British journal of cancer 76 (4), 451-460, 1997 | 171 | 1997 |
| Inhibiting the osteocyte-specific protein sclerostin increases bone mass and fracture resistance in multiple myeloma MM McDonald, MR Reagan, SE Youlten, ST Mohanty, A Seckinger, ... Blood, The Journal of the American Society of Hematology 129 (26), 3452-3464, 2017 | 170 | 2017 |
| Targeting the multiple myeloma hypoxic niche with TH-302, a hypoxia-activated prodrug J Hu, DR Handisides, E Van Valckenborgh, H De Raeve, E Menu, ... Blood, The Journal of the American Society of Hematology 116 (9), 1524-1527, 2010 | 168 | 2010 |
| Chemokine receptor CCR2 is expressed by human multiple myeloma cells and mediates migration to bone marrow stromal cell-produced monocyte chemotactic proteins MCP-1,-2 and-3 IV Broek, K Asosingh, K Vanderkerken, N Straetmans, B Van Camp, ... British journal of cancer 88 (6), 855-862, 2003 | 167 | 2003 |
| Inhibiting activin‐A signaling stimulates bone formation and prevents cancer‐induced bone destruction in vivo AD Chantry, D Heath, AW Mulivor, S Pearsall, M Baud'huin, L Coulton, ... Journal of Bone and Mineral Research 25 (12), 2633-2646, 2010 | 162 | 2010 |
| The 5TMM series: a useful in vivo mouse model of human multiple myeloma. K Asosingh, J Radl, I Van Riet, B Van Camp, K Vanderkerken The hematology journal: the official journal of the European Haematology …, 2000 | 161 | 2000 |
| A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model E Menu, J Garcia, X Huang, M Di Liberto, PL Toogood, I Chen, ... Cancer research 68 (14), 5519-5523, 2008 | 159 | 2008 |
